International Affiliates
Global partners creating a world without T1D
Achieving our vision of a world without T1D requires global collaboration. Approximately 1.45 million Americans live with type 1 diabetes (T1D), and countless more people are affected by the disease around the world. Our five affiliates—Australia, Canada, Israel, the Netherlands, and the United Kingdom—are pivotal partners in funding the research that will reduce the burden of T1D on people’s lives until there is a cure.
JDRF Australia
- More than 126,000 Australians are currently living with T1D, with 8 more people diagnosed each day
- Cases of T1D in Australia are growing by 4.3% per year, compared to the general population growth of 1.4% per year
- Australians with T1D are 5 times more likely to suffer from depression and 1.8 times more likely to suffer from anxiety than someone without T1D
- T1D costs the Australian economy a total of $2.9 billion annually through a range of direct and indirect costs
- To date, JDRF Australia has invested more than $266 million into research across diverse focus areas including disease-modifying therapies, screening for T1D, closed-loop insulin delivery, and more
- JDRF Australia is currently funding more than 50 active research projects across Australia
- JDRF Australia’s advocacy efforts have been instrumental in producing over half a billion dollars of new investment into type 1 diabetes in Australia in the last 10 years
- Supported by the Australian Government, JDRF established The Australian Type 1 Diabetes Clinical Research Network (T1DCRN) to forge global partnerships and bring together world class T1D researchers. The T1DCRN is currently funding more than 30 cutting-edge research projects
Sources:
- Type 1 Diabetes Index; The Economic Cost of Living with T1D report, 2021; JDRF Cure, Treat, Prevent report, 2019; JDRF Financial Reports 2016 – 2020
JDRF Canada
- More than 285,000 Canadians are currently living with T1D
- Cases of T1D in Canada are growing by 4.4% per year, compared to the general population growth of 1.0% per year
- In 1974, a group of parents determined to find a cure for their children living with type 1 diabetes (T1D) came together and began JDRF Canada, launching the largest funder and advocate for T1D research in Canada
- JDRF works every day to change the reality of this disease for millions of people by funding research, advocating for government support of research, new therapies and devices, and connecting the T1D community
- In 2020 JDRF Canada supported 37 active projects in Canada with a total multi-year grant value of approximately $38 million CDN. Of these projects, 30 percent were clinical trials, and another 30 percent were led by postdoctoral fellows—the next generation of Canadian T1D researchers
JDRF The Netherlands
- More than 80,000 people in The Netherlands are currently living with T1D
- Cases of T1D in The Netherlands are growing by 2.8% per year, compared to the general population growth of 0.3% per year
- JDRF The Netherlands was founded 10 years ago by Maarten de Groot, father of a son with T1D
- In 10 years, JDRF spent almost 9 million Euro for scientific research in the Netherlands
JDRF Israel
- More than 23,000 people in Israel are currently living with T1D
- Cases of T1D in Israel are growing by 5.4% per year, compared to the general population growth of 1.9% per year
- JDRF Israel is the only nonprofit organization in Israel that is focused solely on people with T1D
- The organization has partnered with the Israel Science Foundation to establish a $6 million initiative to support T1D research in Israel
JDRF United Kingdom
- The UK has one of the highest rates of T1D in the world, with more than 413,000 people living with the condition
- Cases of T1D in the UK are growing by 3.5% per year, compared to the general population growth of 0.7% per year
- Various world leading T1D researchers are based at UK institutions, including Professor Roman Hovorka at the University of Cambridge, who launched the world’s first licensed artificial pancreas app in 2020
- Former UK Prime Minister, Theresa May, was announced as an ambassador for JDRF UK in 2020
- JDRF UK set up the Connect Immune Research initiative, alongside Versus Arthritis, the MS Society and the British Society for Immunology, to research the links between different autoimmune conditions and accelerate new treatments and cures. The partnership continues to expand as new organizations representing autoimmune conditions join
- In June 2021, the National Health Service (NHS) announced a pilot to support the wider roll out of artificial pancreas technology across England for people with type 1 diabetes, following JDRF UK’s advocacy
- This advocacy operation has also seen all pregnant women with type 1 diabetes in England and Wales provided with continuous glucose monitors via the NHS
